Net Debt Summary of InnoPharmax Inc.

InnoPharmax Inc.'s latest annual net debt in 2023 was -17.85 Million TWD , down -501.08% from previous year.
InnoPharmax Inc.'s latest quarterly net debt in 2024 Q2 was -63.6 Million TWD , up 7.48% from previous quarter.
InnoPharmax Inc. reported annual net debt of -2.97 Million TWD in 2022, up 96.5% from previous year.
InnoPharmax Inc. reported annual net debt of -84.93 Million TWD in 2021, up 43.94% from previous year.
InnoPharmax Inc. reported quarterly net debt of -63.6 Million TWD for 2024 Q2, up 7.48% from previous quarter.
InnoPharmax Inc. reported quarterly net debt of -17.85 Million TWD for 2023 FY, down -501.08% from previous quarter.

Annual Net Debt Chart of InnoPharmax Inc. (2023 - 2019)

Name	Net Debt	Net Debt Difference
Allied Biotech Corporation	178.11 Million TWD	110.026%
GeneFerm Biotechnology Co., Ltd.	31.92 Million TWD	155.936%
Easywell Biomedicals, Inc.	123.43 Million TWD	114.467%
TTY Biopharm Company Limited	-705.97 Million TWD	97.47%
Synmosa Biopharma Corporation	1.52 Billion TWD	101.174%
Orient EuroPharma Co., Ltd.	3.1 Billion TWD	100.575%
Center Laboratories, Inc.	3.91 Billion TWD	100.456%
Tien Liang BioTech Co., Ltd.	-57.55 Million TWD	68.973%
Orient Pharma Co., Ltd.	633.6 Million TWD	102.818%
Johnson Chemical Pharmaceutical Works Co., Ltd.	-926.77 Million TWD	98.073%
Excelsior Biopharma Inc.	-212.51 Million TWD	91.597%
DV Biomed Co., Ltd.	160.7 Million TWD	111.113%
Foresee Pharmaceuticals Co., Ltd.	-781.42 Million TWD	97.715%
Handa Pharmaceuticals, Inc.	-653.8 Million TWD	97.269%
UniPharma Co., Ltd.	-68.36 Million TWD	73.879%
Anxo Pharmaceutical Co., Ltd.	492.4 Million TWD	103.627%
Alar Pharmaceuticals Inc.	-738.05 Million TWD	97.58%
Winston Medical Supply Co., Ltd.	-191.81 Million TWD	90.69%
Mercury Biopharmaceutical Corporation	-1.94 Million TWD	-818.149%
Bioray Biotech Co., Ltd	-27.23 Million TWD	34.423%
TSH Biopharm Corporation Limited	-568.74 Million TWD	96.86%